Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

10.07.23		Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
04.07.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2023 (GlobeNewswire)
30.06.23		Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease (GlobeNewswire)
29.06.23		Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva (GlobeNewswire)
27.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023 (GlobeNewswire)
20.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023 (GlobeNewswire)
14.06.23		Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma (GlobeNewswire)
13.06.23		U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome (GlobeNewswire)
13.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023 (GlobeNewswire)
12.06.23		Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023 (GlobeNewswire)
09.06.23		Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
06.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023 (GlobeNewswire)
01.06.23		Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan (GlobeNewswire)
31.05.23		Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 (GlobeNewswire)
31.05.23		Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023 (GlobeNewswire)
26.05.23		Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. (GlobeNewswire)
17.05.23		Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases (GlobeNewswire)
10.05.23		Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023 (GlobeNewswire)
10.05.23		Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting (GlobeNewswire)
27.04.23		Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance (GlobeNewswire)
24.04.23		Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs (GlobeNewswire)
11.04.23		Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
06.04.23		Ipsen S.A. publishes its 2022 Universal registration document (GlobeNewswire)
16.03.23		Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP (GlobeNewswire)
10.03.23		Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
02.03.23		Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio (GlobeNewswire)
22.02.23		Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 (GlobeNewswire)
15.02.23		Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs (GlobeNewswire)
13.02.23		Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma (GlobeNewswire)
27.01.23		Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23		Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23		Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22		Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22		Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22		Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22		Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22		Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22		Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22		Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22		Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22		Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22		Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
09.06.22		Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury (Businesswire)
01.06.22		Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan (Businesswire)
26.05.22		Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer (Businesswire)
03.05.22		Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer (Businesswire)
27.04.22		Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022 (Businesswire)
25.03.22		Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer (Businesswire)
16.03.22		Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience (Businesswire)
08.03.22		Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide) (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

Nach NVIDIA & Co: Diese beiden Unternehmen könnten den nächsten Aktiensplit erleben

Bitcoin, Ether & Co. in der vergangenen Woche: Wochenbilanz der Kryptowährungen in KW 2

APA - N A C H R I C H T E N Ü B E R B L I C K

Steinmeier setzt Neuwahlen für 23. Februar an

Konkurrenz für D-Wave Quantum: Auf diese Geschäftseinheit von Honeywell hält ein Analyst große Stücke

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	14.01.2025 19:55
Kaufwert:	EUR
	Hinzufügen Speichern